多黏菌素B作为新型黏膜佐剂用于鼻内全灭活流感疫苗
本研究在小鼠模型中探究多黏菌素B(PMB)对全灭活流感病毒(WIIV)鼻内免疫的黏膜佐剂作用。鼻内给予WIIV联合PMB较单用WIIV显著增加黏膜部位病毒特异性IgA抗体分泌细胞数量并升高IgA抗体水平;病毒攻击后所有鼻内免疫WIIV的小鼠存活,WIIV+PMB组维持体重而单用WIIV组出现短暂体重下降;皮下免疫WIIV组仅37.5%存活。结果表明PMB可作为有效黏膜佐剂,黏膜IgA抗体对预防流感病毒感染至关重要。
要点
- 鼻内WIIV+PMB较单用WIIV显著增加黏膜病毒特异性IgA抗体分泌细胞及IgA水平。
- 病毒攻击后鼻内免疫WIIV的小鼠全部存活,WIIV+PMB组维持体重。
- 皮下免疫WIIV组仅37.5%存活,尽管血浆中和活性高于WIIV+PMB组。
核心结论
- PMB与WIIV鼻内共 administration 可诱导强烈的黏膜IgA反应,在年轻成年和幼年小鼠中均提供针对流感病毒攻击的保护。
- 黏膜部位大量病毒特异性IgA抗体而非血浆IgG抗体对预防流感病毒感染至关重要。
研究设计与样本
- 研究采用WIIV免疫的小鼠模型,评估PMB的黏膜佐剂性,以开发新型安全的鼻内流感疫苗。
主要发现
- 鼻内给予WIIV+PMB较单用WIIV显著增加黏膜部位病毒特异性IgA抗体分泌细胞数量,并升高病毒特异性IgA抗体水平。
- 流感病毒攻击后,所有鼻内免疫WIIV的小鼠存活;WIIV+PMB组维持体重,而单用WIIV组出现短暂体重下降。
- 皮下免疫WIIV的小鼠仅37.5%存活,尽管其血浆中和活性高于WIIV+PMB组。
- PMB在幼年小鼠中增强黏膜IgA反应,提示其佐剂作用不依赖年龄。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Influenza poses a significant global health threat, and intranasal vaccines that induce mucosal immunity offer a promising alternative to traditional systemic vaccination. We previously demonstrated the mucosal adjuvanticity of polymyxin B (PMB) for several proteins; however, its potential for whole inactivated influenza virus (WIIV) remains unexplored. The present study aimed to investigate the mucosal adjuvanticity of PMB in a WIIV-immunized mouse model to develop a novel and safe intranasal influenza vaccine. Intranasal administration of WIIV combined with PMB significantly increased the number of virus-specific IgA antibody (Ab)-secreting cells at mucosal sites, thereby elevating the levels of virus-specific IgA Abs compared to the intranasal administration of WIIV alone. Upon influenza virus challenge, all mice immunized intranasally with WIIV survived. Furthermore, the mice intranasally immunized with WIIV + PMB maintained their body weight, unlike those intranasally immunized with WIIV, who experienced transient weight loss. Only 37.5 % of mice subcutaneously immunized with WIIV survived, although they exhibited higher neutralizing activity in plasma than WIIV + PMB mice. These findings demonstrate the potential of PMB as a mucosal adjuvant and indicate that substantial amounts of virus-specific IgA Abs in mucosal compartments, rather than IgG Abs in plasma, are crucial for preventing influenza virus infection. Furthermore, PMB enhanced mucosal IgA response in juvenile mice, suggesting age-independent adjuvanticity. The present study confirms the potential of PMB as an effective mucosal adjuvant when co-administered intranasally with WIIV, inducing robust mucosal IgA responses and protection against influenza challenge in both young adult and juvenile mice.
引用
- Odagiri T, Yoshino N, Sasaki Y, et al. Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine. Vaccine. 2025. PMID: 40957307. doi:10.1016/j.vaccine.2025.127750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。